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Background: Biliary tract cancers (BTCs) are rare and heterogeneous group of tumors classified anatomically
into intrahepatic and extrahepatic bile ducts and gallbladder adenocarcinomas. Patient-derived tumor cell (PDC)
models with genome analysis can be a valuable platform to develop a method to overcome the clinical barrier on
BTCs.Material and Methods: Between January 2012 and June 2015, 40 BTC patients’ samples were collected.
PDCs were isolated and cultured from surgical specimens, biopsy tissues, or malignant effusions including
ascites and pleural fluid. Genome analysis using targeted panel sequencing as well as digital multiplexed gene
analysis was applied to PDCs as well as primary tumors. Results: Extrahepatic cholangiocarcinoma (N = 15,
37.5%), intrahepatic cholangiocarcinoma (N = 10, 25.0%), gallbladder cancer (N = 14, 35.0%), and ampulla of
Vater cancer (N = 1, 2.5%) were included. We identified 15 mutations with diverse genetic alterations in 19
cases of BTC from primary tumor specimens. The most common molecular alterations were in TP53 (8/19,
42.1%), includingmissensemutations such as C242Y, E285K, G112S, P19T, R148T, R248Q, and R273L.We also
detected two NRAS mutations (G12C and Q61L), two KRAS mutations (G12A and G12S), two ERBB2 mutations
(V777L and pM774delinsMA) and amplification, and three PIK3CA mutations (N345K, E545K, and E521K). PDC
models were successfully established in 27 of 40 samples (67.5%), including 22/24 from body fluids (91.7%) and 5/16
from tissue specimens (31.3%). Conclusions: PDC models are promising tools for uncovering driver mutations andResearch Foundation of Korea funded by the Ministry of Education, Science and
Technology (NRF-2013R1A1A2013441).
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174 Genomic Alterations in Biliary Tract Cancer Yoo et al. Translational Oncology Vol. 9, No. 3, 2016identifying rational therapeutic strategies in BTC. Application of this model is expected to inform clinical trials of drugs
for molecular-based targeted therapy.
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Biliary tract cancers (BTCs) are a heterogeneous group of tumors that
affect the intrahepatic and extrahepatic bile ducts and gallbladder [1].
BTCs are rare, but global incidence is rapidly increasing, with greater
frequency in Asia than in Western countries [2,3]. BTCs have poor
prognosis characterized by early lymph node and distal metastases [1].
Although the clinical features of BTCs vary by primary site, surgical
resection is a preferred therapy for all subtypes and offers a potential
cure [4,5]. Because BTCs frequently recur after surgery, radiation
therapy has been suggested for localized disease [6]. Currently,
however, there is no effective adjuvant systemic therapy to our
knowledge [7]. In recurrent or metastatic disease, cytotoxic agents
including 5-fluorouracil, gemcitabine, and platinum have demon-
strated survival benefits over the best standard in supportive care but
show only limited efficacies [8,9]. Recent studies revealed
molecular aberrations associated with BTC carcinogenesis that
may provide molecular targets for treatment [10–12]. However,
because BTCs are diverse diseases, with different genetic
alterations observed for different subtypes, establishing clinical
trial models for targeted therapy is difficult [13]. In addition,
tissue sampling from the biliary tract is challenging because of its
anatomic location [14,15].
Recently, patient-derived tumor cell (PDC) models have been
suggested as preclinical tools for genome-directed targeted therapy.
PDCs are in vitro cell models generated from freshly resected patient
tumors or malignant body fluids that can preserve the histologic and
genomic features of primary tumor cells [16]. The time required to
establish a PDC model is much shorter than that for a patient-derived
xenograft [17]. Furthermore, PDC models can be applied to identify
rational therapeutic options through drug sensitivity tests [16]. In this
study, to overcome the clinical barrier for genetic profiling of BTCs,
we established PDC models from body fluids or tumor tissues
from BTC patients and examined genetic alterations using various
sequencing methods.
Materials and Methods
Patient Consent and Study Inclusion
Between January 2012 and June 2015, 40 patients with BTC
were enrolled in the SMCOncology Biomarker study as previously
described [16,18–20]. All patients were at least 18 years old with
pathologically or cytologically confirmed BTC, which includes
intrahepatic and extrahepatic cholangiocarcinoma, distal common
bile duct cancer, gallbladder adenocarcinoma, and gallbladder
neuroendocrine carcinoma. Tissue specimens were obtained by
surgical resection or liver biopsy, and effusions were percutane-
ously drained for therapeutic purposes and analyzed after
obtaining informed consent. All procedures were carried out
according to guidelines from the Declaration of Helsinki. The
Institutional Review Board at the Samsung Medical Center
approved the protocol.Primary Cultures of Tumor Specimens
For malignant effusions, collected effusions (1 to 5 l) were divided
into 50-ml tubes, centrifuged at 1500 rpm for 10 minutes, and
washed twice with PBS. For surgical specimens, tumors were removed
from surgical specimens then homogenized. Cell pellets were
resuspended in culture medium and plated into 75-cm2 culture
flasks. Cells were grown in RPMI 1640 supplemented with 10%
fetal bovine serum (Gibco BRL, Paisley, UK) and 1% antibiotic-
antimycotic solution (Gibco BRL). The medium was changed every
3 days, and cells were maintained at 37°C in a humidified 5% CO2
incubator. PDCs were passaged using TrypLE Express (Gibco BRL)
to detach cells when the cells reached 80% to 90% confluence.
Targeted Sequencing
Genomic DNA was extracted, and a SureSelect customized kit
(Agilent Technologies, Santa Clara, CA) was used to capture 381
cancer-related genes. An Illumina HiSeq 2500 was used for sequencing
with 100-bp paired-end reads. The sequencing reads were aligned to the
human genome reference sequence (hg19) using BWA (v0.7.5) with
the “MEM” algorithm. We used SAMTOOLS (v0.1.18) and Picard
(v1.93) for sorting SAM/BAM files and duplicate marking, respectively.
Local realignment and base recalibration by GATK (v3.1.1) were
carried out based on dbSNP137, Mills indels, HapMap, and Omni.
Single-nucleotide variations and insertions/deletions were identified
using Mutect (v1.1.4) and Pindel (v0.2.4), respectively. ANNOVAR
was used to annotate the detected variants. Only variants with N1%
allele frequency were included in the results.
Ion AmpliSeq Cancer Panel v2
Adapters 1-96Kit for the nonbarcoded adaptermixwas supplied in the
Ion AmpliSeq Library Kit. The ligated DNA underwent nick translation
and amplification to complete the linkage between adapters and
amplicons and to generate sufficient material for downstream template
preparation. Two rounds of Agencourt AMPure XP Reagent binding at
0.6 and 1.2 bead-to-sample volume ratios removed input DNA and
unincorporated primers from the amplicons. The final library molecules
were 125,300 bp in size. We then transferred the libraries to the Ion
OneTouch System for automated template preparation. Sequencing was
performed on the Ion PGM sequencer according to the manufacturer’s
instructions.We used IonTorrent Software for automated data analysis. A
new pipeline was designed for highly sensitive identification of
single-nucleotide variations for passages 0, 1, and 2. Varscan2 SNP
calling was performed with the following options: min-coverage, 50;
min-var-freq, 0.01; and P value, .1. Variants around the insertions/
deletions were filtered out. Variants were annotated using Oncotator.
Detailed procedures are described in our previous report [21].
nCounter Copy Number Variation CodeSets
For detection of copy number variations, 300 ng purified genomic
DNA extracted from PDCs was analyzed using nCounter Copy
Number Variation CodeSets. DNA was fragmented by AluI digestion
Table 2. Results of IHC and Successful Rate of PDC Models
Patients (N = 40)
IHC of pathologic specimen Total N = 19 0/1+/2+/3+
MUC1 N = 12 5/3/1/3
MUC5AC N = 12 6/1/1/4
MUC6 N = 14 2/3/0/9
P53 N = 12 9/0/0/3
Successful rate of PDC models according
to the type of specimen
27/40 67.5%
Body fluids (ascites or pleural fluid) 22/24 91.7%
Tissue by surgical resection 4/8 50.0%
Tissue by liver biopsy 1/8 12.5%
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codeset of 86 genes in the nCounter Cancer CN Assay Kit
(Nanostring Technologies, Seattle, WA) for 18 hours at 65°C and
processed according to the manufacturer's instructions. An nCounter
Digital Analyzer was used to detect and tabulate the signals of the
reporter probes. Average count numbers N3 were called and
confirmed by immunohistochemistry (IHC), fluorescence in situ
hybridization, or real-time polymerase chain reaction. Validation
results for the nCounter assay were published previously [21].
Statistical Methods
Standard descriptive and analytical methods were used to
describe the patient population and their baseline characteristics.
Progression-free survival (PFS) was defined as the time from the date of
surgery to the date of documented disease progression or death from
any cause. Kaplan-Meier estimates were used to analyze the
time-to-event variables, and the 95% confidence interval (CI) for
the median time to event was computed. Comparisons of survival by
univariate analysis were estimated by the log-rank test. Cox’s
proportional hazard model was used for multivariate analyses.
P b .05 was considered statistically significant, and all P values
correspond to two-sided significance tests. The statistical data were
obtained using SPSS software version 18 (SPSS Inc., Chicago, IL)
Results
Clinical Characteristics of BTC Patients
From January 2012 to June 2015, 40 BTC patient samples were
collected for this study (Table 1). Extrahepatic cholangiocarcinoma
(N = 15, 37.5%), intrahepatic cholangiocarcinoma (N = 10,
25.0%), gallbladder cancer (N = 14, 35.0%), and ampulla of Vater
cancer (N = 1, 2.5%) were included. Twenty patients were initiallyTable 1. Baseline Characteristics
Variables Patients (N = 40) %
Age (year)
Median 61
Range 31-78
Gender
Male 23 57.5%
Female 17 42.5%
Cancer types
Extrahepatic cholangiocarcinoma 15 37.5%
Intrahepatic cholangiocarcinoma 10 25.0%
Gallbladder cancer/ampulla of Vater cancer 15 37.5%
Type of specimen
Tissue by surgical resection 8 20.0%
Tissue by liver biopsy 8 20.0%
Ascites 20 50.0%
Pleural fluid 4 10.0%
Initial stage
I-III 20 50.0%
IV 20 40.0%
Histologic grade
Grade 1 4 10.0%
Grade 2 14 35.0%
Grade 3 16 40.0%
Grade 4 2 5.0%
Unknown 4 10.0%
Disease status at the time of analysis
Recurrence and/or distant metastasis 32 80.0%
No evidence of disease 8 20.0%
CA 19-9 level at the time of PDC N = 37
Median 284
Range 2.43-N140,000diagnosed with stage IV disease, and 20 patients were stage I to III. At
the time of analysis, however, 32 patients had recurrent or metastatic
disease. In 24 patients, liquid biopsy samples were used as a source of
cell culture to establish a PDC model (60.0%: 20 ascites [50.0%] and
4 pleural fluid [10.0%]); tissues from surgical resection (N = 8,
20.0%) or liver biopsy (N = 8, 20.0%) were also used for cell culture.
The median CA 19-9 level at the time of PDC collection was 284
(range: 2.43 to N140,000). IHC for primary pathologic specimens
was performed in 19 patients with variable markers including MUC1,
MUC5AC, MUC6, and P53 (Table 2).
Genomic Analysis on BTC Tumor Specimens
We could successfully analyze the somatic mutation profiles in
primary tumor tissues of 19 of 40 BTC patients because of the limited
amount of tumor tissues or cells. The primary tumor site and the type
of mutations included in the genome analysis were shown in Figure 1.
We performed genomic profiling of primary tumor tissues from
surgical resection or liver biopsy with various analytical methods. The
most common molecular alterations were in TP53 (8/19, 42.1%),
including missense mutations such as C242Y, E285K, G112S, P19T,
R148T, R248Q, and R273L. We also detected two NRAS mutations
(G12C and Q61L), two KRAS mutations (G12A and G12S), two
ERBB2 mutations (V777L and pM774delinsMA) and amplification,
and three PIK3CA mutations (N345K, E545K, and E521K). In case
1, we identified CCND1 amplification, TP53 (C242Y), and
CDKN2A (A128V) mutations as well. FGFR3 amplification with
TP53 (E285K), ERBB2 (V777L), and PIK3CA (E545K) mutations
was detected in case 3 (hilar cholangiocarcinoma). In cases 12 and 16,
amplifications of ERBB2 and CCNE1 were identified, respectively,
without any notable somatic mutations, and both showed strong
HER2 protein overexpression (data not shown). Additionally,
mutations of IDH1 (R132C), RB1 (S576L), and CTNBB1 (S45F)
were accompanied by TP53 mutation. CCND1 amplification, ERBB2
amplification, and CCNE1 amplifications (Figure 1) were perfectly
cross-validated by digital multiplexed gene analysis method (Figure 2).
Establishment of PDCs
PDC models were successfully established in 27 of 40 cases
(67.5%). Successful PDCs were defined as those cells that were
cytologically confirmed by a designated pathologist and maintained
growth following two passages. In body fluids, PDC models were
established in 22 of 24 samples (91.7%). However, the success rates
of PDCs from pathologic specimens were inferior to those of body
fluids: successful cell cultures were achieved in four of eight tissue
samples from surgical resection (50.0%) and only one of eight liver
Figure 1. Genomic landscape of 19 BTC patients. Hilar CCC, hilar cholangiocarcinoma; IC CCC, intrahepatic cholangiocarcinoma; dCBD,
distal common bile duct cancer; GB ADC, gallbladder adenocarcinoma; GB NEC, gallbladder neuroendocrine carcinoma; AoV, ampulla of
Vater; FFPE, formalin-fixed paraffin-embedded; Amp*, amplification; Del†, deletion.
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factors for successful PDC establishment (Table 3). In univariate
analysis, only type of specimen significantly affected success of PDC
establishment (P = .009, hazard ratio = 60.3, 95% CI 2.74-1329.3).
Primary tissue specimens and PDC lines were pathologically similar
to that of pathologically resembled parental tumor. Immunohisto-
chemical staining of CK7 and CK20 in PDCs was well correlated
with that in primary tumors (Figure 3). Morphologically, the progeny
PDCs resembled very well the primary adenocarcinoma of BTC.
Discussion
The current standard of care for metastatic BTC is gemcitabine
plus cisplatin combination therapy (category 1) based on the phase II
trial–demonstrated improvement of PFS compared with gemcitabine
alone (8.0 vs 4.0 months) [8]. Except for 5-fluorouracil–based
regimens, there is no evidence of effective treatment options for
advanced BTC after first-line therapy [22]. For targeted therapy,Figure 2. (A) Immunohistochemistry staining and (B) fluorescence in
(case 19 in Figure 1) (400× magnification).erlotinib, an EGFR-tyrosine kinase inhibitor, showed interesting
activity in combination with gemcitabine and oxaliplatin [23],
demonstrating an objective response rate significantly superior to
chemotherapy alone (30% vs 16%). However, this effect was not
reflected in improvement of PFS and overall survival. Various
subsequent studies with EGFR antibodies and inhibitors have been
attempted in advanced BTC, and agents targeting the VEGF pathway
such as bevacizumab, sorafenib, and sunitinib also have been tested
alone or in combination with gemcitabine-based chemotherapy [24–26].
However, almost all trials demonstratedmarginal efficacies inmetastatic
or advanced BTC patients, and no effective targeted therapies have been
approved at present to our knowledge [11].
Since 2003, several retrospective mutational analyses of BTC
samples have been reported; however, these studies yielded
heterogeneous mutational frequencies influenced by small sample
sizes, the inherent diversity of BTCs, and differences in sequencing
methods [27–29]. Various targetable molecular alterations have beensitu hybridization of HER2 in a patient with ampulla of Vater cancer
Table 3. Univariate Analysis for Success of PDC Establishment
Variables P Value Harzard Ratio (95% CI)
Gender (male vs female) .131 5.08 (0.62-41.7)
Age (≤60 vs N60) .213 4.0 (0.45-35.4)
Location of primary tumor
(GB cancer vs IH CCC vs EH CCC) .743 0.58 (0.023-14.7)
Type of specimen
(body fluids vs surgical specimen vs liver biopsy) .009 60.3 (2.74-1329.3)
Stage (IV vs. I-III) .506 0.26 (0.005-14.05)
Level of CA 19-9 (≤200 vs N200 U/ml) .345 2.05 (0.46-9.0)
Histologic grade (G3-4 vs G1-2) .164 0.36 (0.08-1.52)
GB, gallbladder; IH CCC, intrahepatic cholangiocarcinoma; EH CCC, extrahepatic
cholangiocarcinoma.
Translational Oncology Vol. 9, No. 3, 2016 Genomic Alterations in Biliary Tract Cancer Yoo et al. 177identified by whole exome sequencing, and now clinical trials
targeting PI3K/AKT, MEK/ERK, Hedgehog, and NOTCH path-
ways are being under way [11,30,31]. In addition, a variable degree
of FGFR2 fusion/translocation was also detected in BTCs, and
clinical trials involving an FGFR2 inhibitor are in progress [32]. More
recently, analysis of the genomic spectra of 260 BTC patients in Japan
by a combination of whole exome and transcriptome sequencing
identified genetic alterations in nearly 40% of cases that may become
therapeutic targets [10].
In our study, we observed diverse genomic alterations in 19 cases of
BTC by targeted sequencing. The most commonly detected genomic
alterations were in TP53 (C242Y, E285K, G112S, P19T, R148T,
R248Q, and R273L), NRAS (G12C and Q61L), KRAS (G12A and
G12S), ERBB2 (V777L and pM774delinsMA), and PIK3CA
(N345K, E545K, and E521K). We also identified CCND1
amplification and concomitant TP53 (C242Y) and CDKN2A
(A128V) mutations. There was one case with HER2 amplification
(Figure 2); however, administration of a HER2 inhibitor, lapatinib,
was not effective in inhibiting disease progression. Although a general
conclusion cannot be drawn based on anecdotal experience, this
clinical application based on identification of a genomic alteration
emphasizes the need for clinical decisions to be established using anFigure 3. Immunohistochemical correlation between primary tumo
(upper panel) and PDCs derived from malignant ascites (lower panel
and PDCs derived from malignant pleural effusion (lower panel); (C)
PDCs derived from malignant ascites (lower panel).*Left and right
respectively (400× magnification).integrative approach combining genomic sequencing, pathology,
tumor type, and, if feasible, a preclinical model.
A previous study of PDC models in metastatic cancer reported a
high success rate of PDC establishment with histologic features,
genomic profiles, and functional behaviors similar to those of real
tumors [16]. In the current study, we developed PDC models from
39 BTC patients using body fluids, surgical specimens, or biopsy
specimens. The success rate of PDC models was much higher for
body fluids (N = 22/24, 91.7%) than tissue specimens (N = 5/16,
31.3%) and was particularly low for biopsy tissues (N = 1/8, 12.5%).
Genomic sequencing of PDCs is in progress, and the genetic profiles
of PDCs will be compared with sequencing data from primary
tumors. Nevertheless, we have reported in our previous study using
the same method that the genomic concordance rate between parental
primary and PDC progeny was N80% [16].
There are several limitations in this study. Because a relatively small
number of patients and diverse subtypes of BTC were enrolled, the
results from genomic sequencing data could be interpreted
restrictively. Only a limited number of IHC staining were performed;
therefore, it was difficult to evaluate the correlations between protein
expressions and changes at the molecular level. In conclusion,
we describe a genomic landscape of the BTC cohort that
identified potentially viable targets for treating this disease. In our
future work, we will use genomically profiled patient-derived
preclinical models to screen for drug sensitivity to an array of
molecularly targeted agents to further optimize a genome-based
targeted agent clinical trial for BTC.
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